Forget The Showers. April Brings Flurry of New Cyber Guidance.
Client Alert | 1 min read | 05.01.18
April has marked a busy month for those following the DoD’s approach to contractor cybersecurity. Earlier in the month, the DoD published a much-anticipated revision to their Frequently Asked Questions regarding DFARS 252.204-7012 and other cybersecurity requirements, reflecting feedback on various questions posed by industry over the past year and including new information regarding:
- COTS and commercial items
- Scope of covered defense information
- Conflicts with foreign laws
- Subcontractor flowdowns
- System security plans (SSPs) and plans of action & milestones (POAMs)
- Requirements for FIPS-validation, multifactor authentication, and marking
- Cybersecurity requirements beyond NIST SP 800-171
- Cloud service providers
- Examples of cyber incidents
- Guidance for small businesses
- DCMA oversight
Then just weeks later, the DoD issued proposed guidance for evaluating contractor cybersecurity, including implementation of NIST SP 800-171. Importantly, contractors may comment on the draft guidance through May 31 – and would be well-served to familiarize themselves with the new FAQs before doing so.
Contacts

Partner, Crowell Global Advisors Senior Director
- Washington, D.C.
- D | +1.202.624.2698
- Washington, D.C. (CGA)
- D | +1 202.624.2500
Insights
Client Alert | 5 min read | 02.23.26
UK Government Seeks Evidence on Ownership and Control in Financial Sanctions Regulations
The UK’s Office of Financial Sanctions Implementation (OFSI) has launched a call for evidence concerning the "ownership and control" test within UK financial sanctions. The call for evidence, running until 11:59 p.m. on 13 April 2026, seeks stakeholder views on the challenges and implementation of the "control" limb, with particular focus on its hypothetical element.
Client Alert | 4 min read | 02.20.26
Client Alert | 7 min read | 02.20.26
Section 5949 Proposed Rule Puts the FAR Council's Chips on the Table
Client Alert | 5 min read | 02.20.26
Trump Administration Pursues MFN Pricing for Prescription Drugs

